Ocular Hypertension Following Intravitreal Antivascular Endothelial Growth Factor Therapy: Review of the Literature and Possible Role of Nitric Oxide

Purpose:To review the literature regarding ocular hypertension following intravitreal antivascular endothelial growth factor therapy, and to propose a novel mechanism for the development of ocular hypertension as a result of such therapy. Methods:The PubMed database was used to identify publications by using combinations of the search terms, “glaucoma,” “ocular hypertension,” “pegaptanib,” “bevacizumab,” “ranibizumab,” “aflibercept,” “anti-vascular endothelial growth factor,” intraocular pressure,” and “intravitreal.” The reference lists of these publications were also reviewed for relevant articles. Results:Numerous articles have been published describing ocular hypertension, either immediate-term/short-term or delayed/sustained, following intravitreal antivascular endothelial growth factor therapy. Ocular hypertension has been reported following intravitreal pegaptanib, bevacizumab, and ranibizumab, and aflibercept. On the basis of the fact that vascular endothelial growth factor, normally present as a vascular modulating and reparative growth factor, is known to upregulate endothelial nitric oxide (NO) synthase, and that NO has been shown to decrease intraocular pressure in both normal and glaucomatous human and animal eyes, we propose a novel mechanism for sustained ocular hypertension following intravitreal antivascular endothelial growth factor therapy. We propose that such intravitreal therapy may lead to decreased NO in the anterior segment, which then leads to trabecular meshwork constriction, decreased outflow facility, and increased intraocular pressure. Conclusions:Sustained ocular hypertension following the intravitreal administration of antivascular endothelial growth factor agents is a potentially serious side effect that has not been adequately explained. Further investigation is necessary to determine the role of NO in the mediation of this adverse effect.

[1]  W. Feuer,et al.  Ocular Decompression With Cotton Swabs Lowers Intraocular Pressure Elevation After Intravitreal Injection , 2014, Journal of glaucoma.

[2]  A. Messias,et al.  Comparison of Acetazolamide, Brimonidine, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Initial Intravitreal Bevacizumab Injection: A Randomized Clinical Trial , 2014, Journal of glaucoma.

[3]  D. Denis,et al.  Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure: a comparative clinical study. , 2014, International journal of ophthalmology.

[4]  Paul P. Lee,et al.  Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials. , 2014, Ophthalmology.

[5]  D. Moshfeghi,et al.  Ocular hypertension and intraocular pressure asymmetry after intravitreal injection of anti-vascular endothelial growth factor agents. , 2013, Ophthalmic surgery, lasers & imaging retina.

[6]  Zhangwei Yang,et al.  Safety of Bevacizumab in Treating Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis of All Randomized Clinical Trials , 2013, Clinical Drug Investigation.

[7]  G. Sobacı,et al.  Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure: a comparative clinical study. , 2013, International journal of ophthalmology.

[8]  Douglas J. Rhee,et al.  Soluble Guanylate Cyclase α1–Deficient Mice: A Novel Murine Model for Primary Open Angle Glaucoma , 2013, PloS one.

[9]  S. Wolf,et al.  Long-Term Intraocular Pressure Changes in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab , 2013, Ophthalmologica.

[10]  J. Yoo,et al.  Effect of Dorzolamide/Timolol or Brinzolamide/Timolol Prophylaxis on Intravitreal Anti-VEGF Injection-Induced Intraocular Hypertension , 2013, Seminars in ophthalmology.

[11]  J. R. Ferencz,et al.  Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab. , 2013, The Israel Medical Association journal : IMAJ.

[12]  Jesse J. Jung,et al.  CLINICAL PREDICTORS OF SUSTAINED INTRAOCULAR PRESSURE ELEVATION DUE TO INTRAVITREAL ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY , 2013, Retina.

[13]  P. Kruzliak,et al.  Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension , 2012, Angiogenesis.

[14]  B. Swalduz,et al.  Efficacité d’un traitement prophylactique hypotonisant dans l’hypertonie oculaire induite après injections intravitréennes , 2012 .

[15]  J. García-Feijóo,et al.  Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab. , 2012, Investigative ophthalmology & visual science.

[16]  Ursula Schmidt-Erfurth,et al.  One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. , 2012, Ophthalmology.

[17]  S. Skalicky,et al.  Glaucoma filtration surgery following sustained elevation of intraocular pressure secondary to intravitreal anti-VEGF injections. , 2012, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.

[18]  M. Pistilli,et al.  A LACK OF DELAYED INTRAOCULAR PRESSURE ELEVATION IN PATIENTS TREATED WITH INTRAVITREAL INJECTION OF BEVACIZUMAB AND RANIBIZUMAB , 2012, Retina.

[19]  J. Välimäki,et al.  Effects of pegaptanib injections on intraocular pressure with and without anterior chamber paracentesis: A Prospective Study , 2012, Acta ophthalmologica.

[20]  J. Sorenson,et al.  Sustained Increased Intraocular Pressure Related to Intravitreal Antivascular Endothelial Growth Factor Therapy for Neovascular Age-related Macular Degeneration , 2012, Journal of glaucoma.

[21]  I. Lavi,et al.  Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration , 2012, Graefe's Archive for Clinical and Experimental Ophthalmology.

[22]  Jesse J. Jung,et al.  Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. , 2012, Ophthalmology.

[23]  C. Dot,et al.  [Efficacy of prophylactic treatment of intraocular pressure spikes due to intravitreal injections]. , 2012, Journal francais d'ophtalmologie.

[24]  E. Ongini,et al.  Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models. , 2011, Experimental eye research.

[25]  Andrea Scozzafava,et al.  Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action. , 2011, Bioorganic & medicinal chemistry letters.

[26]  D. Sarraf,et al.  SUSTAINED ELEVATED INTRAOCULAR PRESSURES AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, RANIBIZUMAB, AND PEGAPTANIB , 2011, Retina.

[27]  L. Kodjikian,et al.  "High-molecular-weight aggregates in repackaged bevacizumab". , 2011, Retina.

[28]  M. Apostolopoulos,et al.  Sustained ocular hypertension following intravitreal injections of 0.5 mg/0.05 ml ranibizumab , 2011, International Ophthalmology.

[29]  R. Frenkel,et al.  Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. , 2010, Archives of ophthalmology.

[30]  T. Choueiri,et al.  Suppression of the Nitric Oxide Pathway in Metastatic Renal Cell Carcinoma Patients Receiving Vascular Endothelial Growth Factor–Signaling Inhibitors , 2010, Hypertension.

[31]  N. Sharif,et al.  Endogenous regulation of human Schlemm's canal cell volume by nitric oxide signaling. , 2010, Investigative ophthalmology & visual science.

[32]  Michael B Horsley,et al.  Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. , 2010, American journal of ophthalmology.

[33]  M. Kahook,et al.  In Vitro Effects of Antivascular Endothelial Growth Factors on Cultured Human Trabecular Meshwork Cells , 2010, Journal of glaucoma.

[34]  M. Kahook,et al.  Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents , 2010, British Journal of Ophthalmology.

[35]  M. Kahook,et al.  Sustained Intraocular Pressure Elevation After Intravitreal Injection of Bevacizumab and Ranibizumab Associated with Trabeculitis , 2010, The open ophthalmology journal.

[36]  A. Mirshahi,et al.  Impact of injection techniques on intraocular pressure (IOP) increase after intravitreal ranibizumab application , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[37]  P. Theoulakis,et al.  Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab. , 2010, Klinische Monatsblatter fur Augenheilkunde.

[38]  R. Adelman,et al.  Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. , 2010, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[39]  A. Mirshahi,et al.  Course of Intraocular Pressure after Intravitreal Injection of 0.05 mL Ranibizumab (Lucentis®) , 2010, European journal of ophthalmology.

[40]  M. L. Salvetat,et al.  Short-term Effect of Intravitreal Injection of Ranibizumab (Lucentis) on Intraocular Pressure , 2009, Journal of glaucoma.

[41]  Kihwang Lee,et al.  A PROSPECTIVE STUDY OF BLOOD PRESSURE AND INTRAOCULAR PRESSURE CHANGES IN HYPERTENSIVE AND NONHYPERTENSIVE PATIENTS AFTER INTRAVITREAL BEVACIZUMAB INJECTION , 2009, Retina.

[42]  R. Adelman,et al.  ASSESSMENT OF OPTIC NERVE CUP-TO-DISK RATIO CHANGES IN PATIENTS RECEIVING MULTIPLE INTRAVITREAL INJECTIONS OF ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS , 2009, Retina.

[43]  M. Kahook,et al.  Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. , 2009, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.

[44]  D. Ellis,et al.  Characterization of soluble guanylate cyclase in NO-induced increases in aqueous humor outflow facility and in the trabecular meshwork. , 2009, Investigative ophthalmology & visual science.

[45]  J. Pulido,et al.  Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab , 2007, Eye.

[46]  Judy E. Kim,et al.  Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. , 2008, American journal of ophthalmology.

[47]  D. Ellis,et al.  NO-induced regulation of human trabecular meshwork cell volume and aqueous humor outflow facility involve the BKCa ion channel. , 2008, American journal of physiology. Cell physiology.

[48]  A. Edwards,et al.  Persisent ocular hypertension following intravitreal ranibizumab , 2008, Graefe's Archive for Clinical and Experimental Ophthalmology.

[49]  M. Maier,et al.  Intraocular pressure effects of pegaptanib (macugen) injections in patients with and without glaucoma. , 2008, American journal of ophthalmology.

[50]  H. Hollands,et al.  Short-term intraocular pressure changes after intravitreal injection of bevacizumab. , 2007, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[51]  W. Freeman,et al.  CHANGES OF INTRAOCULAR PRESSURE AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB (AVASTIN) , 2007, Retina.

[52]  H. Izzedine,et al.  Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[53]  A. Neubauer,et al.  Bevacizumab wirkt nicht toxisch auf Zellen des menschlichen Auge , 2007, Der Ophthalmologe.

[54]  M. Maier,et al.  Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. , 2007, Acta ophthalmologica Scandinavica.

[55]  D. McDonald,et al.  Mechanisms of adverse effects of anti-VEGF therapy for cancer , 2007, British Journal of Cancer.

[56]  A. Kampik,et al.  [Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells]. , 2007, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

[57]  G. Shah,et al.  Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection. , 2006, American journal of ophthalmology.

[58]  M. Wiederholt,et al.  Regulation of Trabecular Meshwork Contractility , 2000, Ophthalmologica.

[59]  U. Schlötzer-Schrehardt,et al.  Localization of nitric oxide synthase isoforms in porcine ocular tissues. , 1999, Current eye research.

[60]  H. Granger,et al.  VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. , 1998, American journal of physiology. Heart and circulatory physiology.

[61]  J. Nathanson,et al.  Identification of an extensive system of nitric oxide-producing cells in the ciliary muscle and outflow pathway of the human eye. , 1995, Investigative ophthalmology & visual science.

[62]  J. Nathanson,et al.  Alterations of ocular nitric oxide synthase in human glaucoma. , 1995, Investigative ophthalmology & visual science.

[63]  M. Wiederholt,et al.  Relaxation of trabecular meshwork and ciliary muscle by release of nitric oxide. , 1994, Investigative ophthalmology & visual science.